Laboratory Corp. of America Holdings (NYSE:LH) hit a new 52-week high during trading on Wednesday . The company traded as high as $138.21 and last traded at $137.94, with a volume of 421,140 shares traded. The stock had previously closed at $136.80.

A number of equities research analysts have commented on LH shares. Goldman Sachs Group Inc. increased their price objective on shares of Laboratory Corp. of America Holdings to $119.00 in a report on Wednesday, March 23rd. Canaccord Genuity raised their target price on shares of Laboratory Corp. of America Holdings from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, April 26th. KeyCorp reaffirmed a “buy” rating and issued a $143.00 target price on shares of Laboratory Corp. of America Holdings in a research note on Sunday, May 22nd. Robert W. Baird reaffirmed a “buy” rating on shares of Laboratory Corp. of America Holdings in a research note on Monday, May 16th. Finally, Zacks Investment Research raised shares of Laboratory Corp. of America Holdings from a “hold” rating to a “buy” rating and set a $143.00 target price on the stock in a research note on Tuesday, May 17th. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Laboratory Corp. of America Holdings currently has a consensus rating of “Buy” and a consensus price target of $135.50.

The company has a market cap of $14.18 billion and a PE ratio of 24.01. The company has a 50 day moving average of $130.70 and a 200 day moving average of $120.00.

Laboratory Corp. of America Holdings (NYSE:LH) last released its quarterly earnings data on Monday, April 25th. The company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.06. During the same period last year, the company earned $1.73 EPS. The business earned $2.30 billion during the quarter, compared to the consensus estimate of $2.19 billion. The business’s revenue was up 29.5% on a year-over-year basis. Analysts anticipate that Laboratory Corp. of America Holdings will post $8.79 earnings per share for the current fiscal year.

In other news, CEO David P. King sold 196,400 shares of the company’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $128.00, for a total value of $25,139,200.00. Following the completion of the transaction, the chief executive officer now owns 271,210 shares of the company’s stock, valued at $34,714,880. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Edward T. Dodson sold 9,392 shares of the company’s stock in a transaction dated Wednesday, April 27th. The stock was sold at an average price of $126.42, for a total value of $1,187,336.64. Following the completion of the transaction, the insider now directly owns 2,717 shares of the company’s stock, valued at approximately $343,483.14. The disclosure for this sale can be found here.

A number of institutional investors have recently made changes to their positions in LH. Mutual of America Capital Management LLC raised its position in shares of Laboratory Corp. of America Holdings by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 11,272 shares of the company’s stock worth $1,394,000 after buying an additional 61 shares during the last quarter. Gulf International Bank UK Ltd raised its position in shares of Laboratory Corp. of America Holdings by 3.5% in the fourth quarter. Gulf International Bank UK Ltd now owns 29,581 shares of the company’s stock worth $3,657,000 after buying an additional 1,010 shares during the last quarter. White Pine Investment CO raised its position in shares of Laboratory Corp. of America Holdings by 212.3% in the fourth quarter. White Pine Investment CO now owns 18,675 shares of the company’s stock worth $2,309,000 after buying an additional 12,695 shares during the last quarter. American National Bank & Trust Co. VA raised its position in shares of Laboratory Corp. of America Holdings by 1.0% in the fourth quarter. American National Bank & Trust Co. VA now owns 27,418 shares of the company’s stock worth $3,390,000 after buying an additional 274 shares during the last quarter. Finally, Mizuho Trust & Banking Co. Ltd. raised its position in shares of Laboratory Corp. of America Holdings by 0.9% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 145,749 shares of the company’s stock worth $18,101,000 after buying an additional 1,262 shares during the last quarter.

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.